Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Lijun International Pharmaceutical
Shijiazhuang, Hebei, Chinalijun.com.hk ↗
- Ownership
- Private
- Employees
- ~3600
- Development stage
- Other
01
Overview
The company is China’s largest manufacturer of macrolide antibiotics, maintains leadership in intravenous infusion solutions for hospital use, and produces a diverse portfolio of antibiotics, infusions, and select non-antibiotic finished medicines, with Chinese FDA and US FDA approval on several products. Enerxin Capsule was recognized as effective against Influenza A (H1N1)[3][5][8].
- Therapeutic areas
- ImmunologyInfectious DiseasesCardiovascular
- Modalities
- Small moleculeBiologicModern Chinese traditional medicine
- Industry
- Pharma
Beyond the preview
Go deeper on Lijun International Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lijun International Pharmaceutical.